Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $50.04 million versus the consensus estimate of $61.02 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $222.9 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.